TY - JOUR AU - Prahallad, A. AU - Sun, C. AU - Huang, S. AU - Nicolantonio, F. AU - Salazar, R. AU - Zecchin, D. PY - 2012 DA - 2012// TI - Unresponsiveness of colon cancer to BRAF[V600E] inhibition through feedback activation of EGFR JO - Nature VL - 483 ID - Prahallad2012 ER - TY - JOUR AU - Lynch, T. J. AU - Bell, D. W. AU - Sordella, R. AU - Gurubhagavatula, S. AU - Okimoto, R. A. AU - Brannigan, B. W. PY - 2004 DA - 2004// TI - Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib JO - N Engl J Med VL - 350 ID - Lynch2004 ER - TY - JOUR AU - Soda, M. AU - Choi, Y. L. AU - Enomoto, M. AU - Takada, S. AU - Yamashita, Y. AU - Ishikawa, S. PY - 2007 DA - 2007// TI - Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer JO - Nature VL - 448 ID - Soda2007 ER - TY - JOUR AU - Corcoran, R. B. AU - Ebi, H. AU - Turke, A. B. AU - Coffee, E. M. AU - Nishino, M. AU - Cogdill, A. P. PY - 2012 DA - 2012// TI - EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib JO - Cancer Discov VL - 2 ID - Corcoran2012 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2000 DA - 2000// TI - The hallmarks of cancer JO - Cell VL - 100 ID - Hanahan2000 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 ID - Hanahan2011 ER - TY - JOUR AU - Yarden, Y. AU - Sliwkowski, M. X. PY - 2001 DA - 2001// TI - Untangling the ErbB signalling network JO - Nat Rev Mol Cell Biol VL - 2 ID - Yarden2001 ER - TY - JOUR AU - Yarden, Y. PY - 2001 DA - 2001// TI - The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities JO - Eur J Cancer VL - 37 ID - Yarden2001 ER - TY - JOUR AU - Henriksen, L. AU - Grandal, M. V. AU - Knudsen, S. L. AU - Deurs, B. AU - Grovdal, L. M. PY - 2013 DA - 2013// TI - Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands JO - PLoS One VL - 8 ID - Henriksen2013 ER - TY - JOUR AU - McCourt, C. M. AU - Boyle, D. AU - James, J. AU - Salto-Tellez, M. PY - 2013 DA - 2013// TI - Immunohistochemistry in the era of personalised medicine JO - J Clin Pathol VL - 66 ID - McCourt2013 ER - TY - JOUR AU - Anagnostou, V. K. AU - Welsh, A. W. AU - Giltnane, J. M. AU - Siddiqui, S. AU - Liceaga, C. AU - Gustavson, M. PY - 2010 DA - 2010// TI - Analytic variability in immunohistochemistry biomarker studies JO - Cancer Epidemiol Biomarkers Prev VL - 19 ID - Anagnostou2010 ER - TY - JOUR AU - Rivenbark, A. G. AU - O’Connor, S. M. AU - Coleman, W. B. PY - 2013 DA - 2013// TI - Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine JO - Am J Pathol VL - 183 ID - Rivenbark2013 ER - TY - JOUR AU - Vogelstein, B. AU - Papadopoulos, N. AU - Velculescu, V. E. AU - Zhou, S. AU - Diaz, L. A. AU - Kinzler, K. W. PY - 2013 DA - 2013// TI - Cancer genome landscapes JO - Science VL - 339 ID - Vogelstein2013 ER - TY - JOUR AU - Burrell, R. A. AU - McGranahan, N. AU - Bartek, J. AU - Swanton, C. PY - 2013 DA - 2013// TI - The causes and consequences of genetic heterogeneity in cancer evolution JO - Nature VL - 501 ID - Burrell2013 ER - TY - JOUR AU - Aparicio, S. AU - Caldas, C. PY - 2013 DA - 2013// TI - The implications of clonal genome evolution for cancer medicine JO - N Engl J Med VL - 368 ID - Aparicio2013 ER - TY - JOUR AU - Almendro, V. AU - Marusyk, A. AU - Polyak, K. PY - 2013 DA - 2013// TI - Cellular heterogeneity and molecular evolution in cancer JO - Annu Rev Pathol VL - 24 ID - Almendro2013 ER - TY - JOUR AU - Bruin, E. C. AU - Taylor, T. B. AU - Swanton, C. PY - 2013 DA - 2013// TI - Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications JO - Genome Med VL - 5 ID - Bruin2013 ER - TY - JOUR AU - Gerlinger, M. AU - Rowan, A. J. AU - Horswell, S. AU - Larkin, J. AU - Endesfelder, D. AU - Gronroos, E. PY - 2012 DA - 2012// TI - Intratumor heterogeneity and branched evolution revealed by multiregion sequencing JO - N Engl J Med VL - 366 ID - Gerlinger2012 ER - TY - JOUR AU - Fisher, R. AU - Pusztai, L. AU - Swanton, C. PY - 2013 DA - 2013// TI - Cancer heterogeneity: implications for targeted therapeutics JO - Br J Cancer VL - 108 ID - Fisher2013 ER - TY - JOUR AU - Maughan, T. S. AU - Adams, R. A. AU - Smith, C. G. AU - Meade, A. M. AU - Seymour, M. T. AU - Wilson, R. H. PY - 2011 DA - 2011// TI - Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial JO - Lancet VL - 377 ID - Maughan2011 ER - TY - JOUR AU - Seymour, M. T. AU - Maughan, T. S. AU - Ledermann, J. A. AU - Topham, C. AU - James, R. AU - Gwyther, S. J. PY - 2007 DA - 2007// TI - Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer [MRC FOCUS]: a randomised controlled trial JO - Lancet VL - 370 ID - Seymour2007 ER - TY - JOUR AU - Fitzgibbons, P. L. AU - Lazar, A. J. AU - Spencer, S. PY - 2014 DA - 2014// TI - Introducing new College of American Pathologists reporting templates for cancer biomarkers JO - Arch Pathol Lab Med VL - 138 ID - Fitzgibbons2014 ER - TY - JOUR AU - Idikio, H. A. PY - 2009 DA - 2009// TI - Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains JO - Int J Clin Exp Pathol VL - 3 ID - Idikio2009 ER - TY - JOUR AU - Russnes, H. G. AU - Navin, N. AU - Hicks, J. AU - Borresen-Dale, A. L. PY - 2011 DA - 2011// TI - Insight into the heterogeneity of breast cancer through next-generation sequencing JO - J Clin Invest VL - 121 ID - Russnes2011 ER - TY - JOUR AU - Thomson, T. A. AU - Hayes, M. M. AU - Spinelli, J. J. AU - Hilland, E. AU - Sawrenko, C. AU - Phillips, D. PY - 2001 DA - 2001// TI - HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization JO - Mod Pathol VL - 14 ID - Thomson2001 ER - TY - JOUR AU - Turashvili, G. AU - Leung, S. AU - Turbin, D. AU - Montgomery, K. AU - Gilks, B. AU - West, R. PY - 2009 DA - 2009// TI - Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization [FISH]: pathologist assessment compared to quantitative image analysis JO - BMC Cancer VL - 9 ID - Turashvili2009 ER - TY - JOUR AU - Gavrielides, M. A. AU - Gallas, B. D. AU - Lenz, P. AU - Badano, A. AU - Hewitt, S. M. PY - 2011 DA - 2011// TI - Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computer-aided digital microscopy JO - Arch Pathol Lab Med VL - 135 ID - Gavrielides2011 ER - TY - JOUR AU - Atkins, D. AU - Reiffen, K. A. AU - Tegtmeier, C. L. AU - Winther, H. AU - Bonato, M. S. AU - Storkel, S. PY - 2004 DA - 2004// TI - Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections JO - J Histochem Cytochem VL - 52 ID - Atkins2004 ER - TY - JOUR AU - Hewitt, S. M. AU - Badve, S. S. AU - True, L. D. PY - 2012 DA - 2012// TI - Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy JO - Clin Cancer Res VL - 18 ID - Hewitt2012 ER - TY - JOUR AU - Neumeister, V. M. AU - Parisi, F. AU - England, A. M. AU - Siddiqui, S. AU - Anagnostou, V. AU - Zarrella, E. PY - 2014 DA - 2014// TI - A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue JO - Lab Invest VL - 94 ID - Neumeister2014 ER - TY - JOUR AU - Press, M. F. AU - Hung, G. AU - Godolphin, W. AU - Slamon, D. J. PY - 1994 DA - 1994// TI - Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression JO - Cancer Res VL - 54 ID - Press1994 ER - TY - JOUR AU - Tong, L. C. AU - Nelson, N. AU - Tsourigiannis, J. AU - Mulligan, A. M. PY - 2011 DA - 2011// TI - The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study JO - Am J Surg Pathol VL - 35 ID - Tong2011 ER - TY - JOUR AU - Wolff, A. C. AU - Hammond, M. E. AU - Schwartz, J. N. AU - Hagerty, K. L. AU - Allred, D. C. AU - Cote, R. J. PY - 2007 DA - 2007// TI - American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer JO - J Clin Oncol VL - 25 ID - Wolff2007 ER - TY - JOUR AU - Wolff, A. C. AU - Hammond, M. E. AU - Hicks, D. G. AU - Dowsett, M. AU - McShane, L. M. AU - Allison, K. H. PY - 2013 DA - 2013// TI - Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update JO - J Clin Oncol VL - 31 ID - Wolff2013 ER - TY - JOUR AU - Hammond, M. E. AU - Hayes, D. F. AU - Wolff, A. C. AU - Mangu, P. B. AU - Temin, S. PY - 2010 DA - 2010// TI - American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer JO - J Oncol Pract VL - 6 ID - Hammond2010 ER - TY - JOUR AU - Allred, D. C. AU - Harvey, J. M. AU - Berardo, M. AU - Clark, G. M. PY - 1998 DA - 1998// TI - Prognostic and predictive factors in breast cancer by immunohistochemical analysis JO - Mod Pathol VL - 11 ID - Allred1998 ER - TY - JOUR AU - Dowsett, M. AU - Nielsen, T. O. AU - A’Hern, R. AU - Bartlett, J. AU - Coombes, R. C. AU - Cuzick, J. PY - 2011 DA - 2011// TI - Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group JO - J Natl Cancer Inst VL - 103 ID - Dowsett2011 ER - TY - JOUR AU - Won, J. R. AU - Gao, D. AU - Grant, D. AU - Cupples, J. AU - Rahemtulla, A. AU - Wolber, R. PY - 2012 DA - 2012// TI - Variable performance of commercial epidermal growth factor receptor antibodies in detection of basal-like breast cancer JO - Histopathology VL - 61 ID - Won2012 ER - TY - JOUR AU - Ciardiello, F. AU - Tortora, G. PY - 2003 DA - 2003// TI - Epidermal growth factor receptor [EGFR] as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs JO - Eur J Cancer VL - 39 ID - Ciardiello2003 ER - TY - JOUR AU - Ciardiello, F. AU - Tortora, G. PY - 2008 DA - 2008// TI - EGFR antagonists in cancer treatment JO - N Engl J Med VL - 358 ID - Ciardiello2008 ER - TY - JOUR AU - Saltz, L. B. AU - Meropol, N. J. AU - Loehrer, P. J. S. AU - Needle, M. N. AU - Kopit, J. AU - Mayer, R. J. PY - 2004 DA - 2004// TI - Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor JO - J Clin Oncol VL - 22 ID - Saltz2004 ER - TY - JOUR AU - Cutsem, E. AU - Peeters, M. AU - Siena, S. AU - Humblet, Y. AU - Hendlisz, A. AU - Neyns, B. PY - 2007 DA - 2007// TI - Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer JO - J Clin Oncol VL - 25 ID - Cutsem2007 ER - TY - JOUR AU - Pirker, R. AU - Pereira, J. R. AU - Pawel, J. AU - Krzakowski, M. AU - Ramlau, R. AU - Park, K. PY - 2012 DA - 2012// TI - EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study JO - Lancet Oncol VL - 13 ID - Pirker2012 ER - TY - STD TI - You B, Chen EX (2011) Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab. J Clin Pharmacol ID - ref44 ER - TY - JOUR AU - Cunningham, D. AU - Humblet, Y. AU - Siena, S. AU - Khayat, D. AU - Bleiberg, H. AU - Santoro, A. PY - 2004 DA - 2004// TI - Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer JO - N Engl J Med VL - 351 ID - Cunningham2004 ER - TY - JOUR AU - Amado, R. G. AU - Wolf, M. AU - Peeters, M. AU - Cutsem, E. AU - Siena, S. AU - Freeman, D. J. PY - 2008 DA - 2008// TI - Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer JO - J Clin Oncol VL - 26 ID - Amado2008 ER - TY - JOUR AU - Lievre, A. AU - Bachet, J. B. AU - Corre, D. AU - Boige, V. AU - Landi, B. AU - Emile, J. F. PY - 2006 DA - 2006// TI - KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer JO - Cancer Res VL - 66 ID - Lievre2006 ER - TY - JOUR AU - Lievre, A. AU - Bachet, J. B. AU - Boige, V. AU - Cayre, A. AU - Corre, D. AU - Buc, E. PY - 2008 DA - 2008// TI - KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab JO - J Clin Oncol VL - 26 ID - Lievre2008 ER - TY - JOUR AU - Fiore, F. AU - Blanchard, F. AU - Charbonnier, F. AU - Pessot, F. AU - Lamy, A. AU - Galais, M. P. PY - 2007 DA - 2007// TI - Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy JO - Br J Cancer VL - 96 ID - Fiore2007 ER - TY - JOUR AU - Douillard, J. Y. AU - Oliner, K. S. AU - Siena, S. AU - Tabernero, J. AU - Burkes, R. AU - Barugel, M. PY - 2013 DA - 2013// TI - Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer JO - N Engl J Med VL - 369 ID - Douillard2013 ER - TY - JOUR AU - Douillard, J. Y. AU - Siena, S. AU - Cassidy, J. AU - Tabernero, J. AU - Burkes, R. AU - Barugel, M. PY - 2010 DA - 2010// TI - Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin [FOLFOX4] versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study JO - J Clin Oncol VL - 28 ID - Douillard2010 ER - TY - JOUR AU - Bokemeyer, C. AU - Bondarenko, I. AU - Hartmann, J. T. AU - Braud, F. AU - Schuch, G. AU - Zubel, A. PY - 2011 DA - 2011// TI - Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study JO - Ann Oncol VL - 22 ID - Bokemeyer2011 ER - TY - JOUR AU - Stintzing, S. AU - Fischer von Weikersthal, L. AU - Decker, T. AU - Vehling-Kaiser, U. AU - Jager, E. AU - Heintges, T. PY - 2012 DA - 2012// TI - FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306 JO - Ann Oncol VL - 23 ID - Stintzing2012 ER - TY - JOUR AU - Bokemeyer, C. AU - Bondarenko, I. AU - Makhson, A. AU - Hartmann, J. T. AU - Aparicio, J. AU - Braud, F. PY - 2009 DA - 2009// TI - Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer JO - J Clin Oncol VL - 27 ID - Bokemeyer2009 ER - TY - JOUR AU - Jonker, D. J. AU - O’Callaghan, C. J. AU - Karapetis, C. S. AU - Zalcberg, J. R. AU - Tu, D. AU - Au, H. J. PY - 2007 DA - 2007// TI - Cetuximab for the treatment of colorectal cancer JO - N Engl J Med VL - 357 ID - Jonker2007 ER - TY - JOUR AU - Karapetis, C. S. AU - Khambata-Ford, S. AU - Jonker, D. J. AU - O’Callaghan, C. J. AU - Tu, D. AU - Tebbutt, N. C. PY - 2008 DA - 2008// TI - K-ras mutations and benefit from cetuximab in advanced colorectal cancer JO - N Engl J Med VL - 359 ID - Karapetis2008 ER - TY - JOUR AU - Roock, W. AU - Claes, B. AU - Bernasconi, D. AU - Schutter, J. AU - Biesmans, B. AU - Fountzilas, G. PY - 2010 DA - 2010// TI - Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis JO - Lancet Oncol VL - 11 ID - Roock2010 ER - TY - JOUR AU - Roock, W. AU - Vriendt, V. AU - Normanno, N. AU - Ciardiello, F. AU - Tejpar, S. PY - 2011 DA - 2011// TI - KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer JO - Lancet Oncol VL - 12 ID - Roock2011 ER - TY - JOUR AU - Vale, C. L. AU - Tierney, J. F. AU - Fisher, D. AU - Adams, R. A. AU - Kaplan, R. AU - Maughan, T. S. PY - 2012 DA - 2012// TI - Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis JO - Cancer Treat Rev VL - 38 ID - Vale2012 ER - TY - JOUR AU - Chung, K. Y. AU - Shia, J. AU - Kemeny, N. E. AU - Shah, M. AU - Schwartz, G. K. AU - Tse, A. PY - 2005 DA - 2005// TI - Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry JO - J Clin Oncol VL - 23 ID - Chung2005 ER - TY - JOUR AU - Wierzbicki, R. AU - Jonker, D. J. AU - Moore, M. J. AU - Berry, S. R. AU - Loehrer, P. J. AU - Youssoufian, H. PY - 2011 DA - 2011// TI - A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining JO - Invest New Drugs VL - 29 ID - Wierzbicki2011 ER - TY - JOUR AU - Cunningham, M. P. AU - Essapen, S. AU - Thomas, H. AU - Green, M. AU - Lovell, D. P. AU - Topham, C. PY - 2005 DA - 2005// TI - Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer JO - Int J Oncol VL - 27 ID - Cunningham2005 ER - TY - JOUR AU - Allo, G. AU - Bandarchi, B. AU - Yanagawa, N. AU - Wang, A. AU - Shih, W. AU - Xu, J. PY - 2014 DA - 2014// TI - EGFR mutation-specific immunohistochemical antibodies in lung adenocarcinoma JO - Histopathology VL - 64 ID - Allo2014 ER - TY - JOUR AU - Brabyn, C. J. AU - Kleine, L. P. PY - 1995 DA - 1995// TI - EGF causes hyperproliferation and apoptosis in T51B cells: involvement of high and low affinity EGFR binding sites JO - Cell Signal VL - 7 ID - Brabyn1995 ER - TY - JOUR AU - Braun, S. AU - Schlimok, G. AU - Heumos, I. AU - Schaller, G. AU - Riethdorf, L. AU - Riethmuller, G. PY - 2001 DA - 2001// TI - ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients JO - Cancer Res VL - 61 ID - Braun2001 ER - TY - JOUR AU - Ithimakin, S. AU - Day, K. C. AU - Malik, F. AU - Zen, Q. AU - Dawsey, S. J. AU - Bersano-Begey, T. F. PY - 2013 DA - 2013// TI - HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab JO - Cancer Res VL - 73 ID - Ithimakin2013 ER - TY - JOUR AU - Hirsch, F. R. AU - Varella-Garcia, M. AU - Bunn, P. A. AU - Maria, M. V. AU - Veve, R. AU - Bremmes, R. M. PY - 2003 DA - 2003// TI - Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis JO - J Clin Oncol VL - 21 ID - Hirsch2003 ER - TY - JOUR AU - Hirsch, F. R. AU - Herbst, R. S. AU - Olsen, C. AU - Chansky, K. AU - Crowley, J. AU - Kelly, K. PY - 2008 DA - 2008// TI - Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy JO - J Clin Oncol VL - 26 ID - Hirsch2008 ER - TY - JOUR AU - Wulf, M. A. AU - Bode, B. AU - Zimmermann, D. AU - Rufibach, K. AU - Weder, W. AU - Moch, H. PY - 2012 DA - 2012// TI - Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer JO - Am J Surg Pathol VL - 36 ID - Wulf2012 ER - TY - JOUR AU - Algars, A. AU - Lintunen, M. AU - Carpen, O. AU - Ristamaki, R. AU - Sundstrom, J. PY - 2011 DA - 2011// TI - EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer JO - Br J Cancer VL - 105 ID - Algars2011 ER - TY - JOUR AU - Werner, M. AU - Chott, A. AU - Fabiano, A. AU - Battifora, H. PY - 2000 DA - 2000// TI - Effect of formalin tissue fixation and processing on immunohistochemistry JO - Am J Surg Pathol VL - 24 ID - Werner2000 ER - TY - JOUR AU - Liotta, L. A. AU - Espina, V. AU - Mehta, A. I. AU - Calvert, V. AU - Rosenblatt, K. AU - Geho, D. PY - 2003 DA - 2003// TI - Protein microarrays: meeting analytical challenges for clinical applications JO - Cancer Cell VL - 3 ID - Liotta2003 ER - TY - JOUR AU - Sartore-Bianchi, A. AU - Fieuws, S. AU - Veronese, S. AU - Moroni, M. AU - Personeni, N. AU - Frattini, M. PY - 2012 DA - 2012// TI - Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study JO - J Clin Pathol VL - 65 ID - Sartore-Bianchi2012 ER - TY - JOUR AU - Sartore-Bianchi, A. AU - Moroni, M. AU - Veronese, S. AU - Carnaghi, C. AU - Bajetta, E. AU - Luppi, G. PY - 2007 DA - 2007// TI - Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab JO - J Clin Oncol VL - 25 ID - Sartore-Bianchi2007 ER - TY - JOUR AU - Luber, B. AU - Deplazes, J. AU - Keller, G. AU - Walch, A. AU - Rauser, S. AU - Eichmann, M. PY - 2011 DA - 2011// TI - Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie [AIO] JO - BMC Cancer VL - 11 ID - Luber2011 ER - TY - JOUR AU - Personeni, N. AU - Fieuws, S. AU - Piessevaux, H. AU - Hertogh, G. AU - Schutter, J. AU - Biesmans, B. PY - 2008 DA - 2008// TI - Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study JO - Clin Cancer Res VL - 14 ID - Personeni2008 ER - TY - JOUR AU - Mahipal, A. AU - Mcdonald, M. J. AU - Witkiewicz, A. AU - Carr, B. I. PY - 2012 DA - 2012// TI - Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma JO - Med Oncol VL - 29 ID - Mahipal2012 ER - TY - JOUR AU - Pu, Y. S. AU - Huang, C. Y. AU - Kuo, Y. Z. AU - Kang, W. Y. AU - Liu, G. Y. AU - Huang, A. M. PY - 2009 DA - 2009// TI - Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma JO - J Biomed Sci VL - 16 ID - Pu2009 ER - TY - JOUR AU - Ueda, S. AU - Ogata, S. AU - Tsuda, H. AU - Kawarabayashi, N. AU - Kimura, M. AU - Sugiura, Y. PY - 2004 DA - 2004// TI - The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma JO - Pancreas VL - 29 ID - Ueda2004 ER - TY - JOUR AU - Spano, J. P. AU - Fagard, R. AU - Soria, J. C. AU - Rixe, O. AU - Khayat, D. AU - Milano, G. PY - 2005 DA - 2005// TI - Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives JO - Ann Oncol VL - 16 ID - Spano2005 ER - TY - JOUR AU - Slamon, D. J. AU - Leyland-Jones, B. AU - Shak, S. AU - Fuchs, H. AU - Paton, V. AU - Bajamonde, A. PY - 2001 DA - 2001// TI - Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 JO - N Engl J Med VL - 344 ID - Slamon2001 ER - TY - JOUR AU - Slamon, D. AU - Eiermann, W. AU - Robert, N. AU - Pienkowski, T. AU - Martin, M. AU - Press, M. PY - 2011 DA - 2011// TI - Adjuvant trastuzumab in HER2-positive breast cancer JO - N Engl J Med VL - 365 ID - Slamon2011 ER - TY - JOUR AU - Mosesson, Y. AU - Mills, G. B. AU - Yarden, Y. PY - 2008 DA - 2008// TI - Derailed endocytosis: an emerging feature of cancer JO - Nat Rev Cancer VL - 8 ID - Mosesson2008 ER - TY - JOUR AU - Liao, H. J. AU - Carpenter, G. PY - 2009 DA - 2009// TI - Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor JO - Cancer Res VL - 69 ID - Liao2009 ER - TY - JOUR AU - Tomas, A. AU - Futter, C. E. AU - Eden, E. R. PY - 2014 DA - 2014// TI - EGF receptor trafficking: consequences for signaling and cancer JO - Trends Cell Biol VL - 24 ID - Tomas2014 ER - TY - JOUR AU - Piyathilake, C. J. AU - Frost, A. R. AU - Manne, U. AU - Weiss, H. AU - Bell, W. C. AU - Heimburger, D. C. PY - 2002 DA - 2002// TI - Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung JO - Clin Cancer Res VL - 8 ID - Piyathilake2002 ER - TY - JOUR AU - Einama, T. AU - Ueda, S. AU - Tsuda, H. AU - Ogasawara, K. AU - Hatsuse, K. AU - Matsubara, O. PY - 2012 DA - 2012// TI - Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma JO - Exp Ther Med VL - 3 ID - Einama2012 ER - TY - JOUR AU - Craene, B. AU - Berx, G. PY - 2013 DA - 2013// TI - Regulatory networks defining EMT during cancer initiation and progression JO - Nat Rev Cancer VL - 13 ID - Craene2013 ER - TY - JOUR AU - Lamouille, S. AU - Xu, J. AU - Derynck, R. PY - 2014 DA - 2014// TI - Molecular mechanisms of epithelial-mesenchymal transition JO - Nat Rev Mol Cell Biol VL - 15 ID - Lamouille2014 ER - TY - JOUR AU - Mendoza, M. C. AU - Er, E. E. AU - Blenis, J. PY - 2011 DA - 2011// TI - The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation JO - Trends Biochem Sci VL - 36 ID - Mendoza2011 ER - TY - JOUR AU - Vartanian, S. AU - Bentley, C. AU - Brauer, M. J. AU - Li, L. AU - Shirasawa, S. AU - Sasazuki, T. PY - 2013 DA - 2013// TI - Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines JO - J Biol Chem VL - 288 ID - Vartanian2013 ER - TY - JOUR AU - Parsons, B. L. AU - Myers, M. B. PY - 2013 DA - 2013// TI - Personalized cancer treatment and the myth of KRAS wild-type colon tumors JO - Discov Med VL - 15 ID - Parsons2013 ER - TY - JOUR AU - Heinemann, V. AU - Weikersthal, L. F. AU - Decker, T. AU - Kiani, A. AU - Vehling-Kaiser, U. AU - Al-Batran, S. E. PY - 2014 DA - 2014// TI - FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer [FIRE-3]: a randomised, open-label, phase 3 trial JO - Lancet Oncol VL - 15 ID - Heinemann2014 ER - TY - JOUR AU - Vogelstein, B. AU - Fearon, E. R. AU - Hamilton, S. R. AU - Kern, S. E. AU - Preisinger, A. C. AU - Leppert, M. PY - 1988 DA - 1988// TI - Genetic alterations during colorectal-tumor development JO - N Engl J Med VL - 319 ID - Vogelstein1988 ER - TY - JOUR AU - Fearon, E. R. AU - Vogelstein, B. PY - 1990 DA - 1990// TI - A genetic model for colorectal tumorigenesis JO - Cell VL - 61 ID - Fearon1990 ER - TY - JOUR PY - 2012 DA - 2012// TI - Comprehensive molecular characterization of human colon and rectal cancer JO - Nature VL - 487 ID - ref96 ER - TY - JOUR AU - Schreiber, R. D. AU - Old, L. J. AU - Smyth, M. J. PY - 2011 DA - 2011// TI - Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion JO - Science VL - 331 ID - Schreiber2011 ER - TY - JOUR AU - Liotta, L. A. AU - Kohn, E. C. PY - 2001 DA - 2001// TI - The microenvironment of the tumour-host interface JO - Nature VL - 411 ID - Liotta2001 ER - TY - JOUR AU - Emens, L. A. AU - Silverstein, S. C. AU - Khleif, S. AU - Marincola, F. M. AU - Galon, J. PY - 2012 DA - 2012// TI - Toward integrative cancer immunotherapy: targeting the tumor microenvironment JO - J Transl Med VL - 10 ID - Emens2012 ER - TY - JOUR AU - Galon, J. AU - Fridman, W. H. AU - Pages, F. PY - 2007 DA - 2007// TI - The adaptive immunologic microenvironment in colorectal cancer: a novel perspective JO - Cancer Res VL - 67 ID - Galon2007 ER - TY - JOUR AU - Mlecnik, B. AU - Tosolini, M. AU - Kirilovsky, A. AU - Berger, A. AU - Bindea, G. AU - Meatchi, T. PY - 2011 DA - 2011// TI - Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction JO - J Clin Oncol VL - 29 ID - Mlecnik2011 ER - TY - JOUR AU - Galon, J. AU - Costes, A. AU - Sanchez-Cabo, F. AU - Kirilovsky, A. AU - Mlecnik, B. AU - Lagorce-Pages, C. PY - 2006 DA - 2006// TI - Type, density, and location of immune cells within human colorectal tumors predict clinical outcome JO - Science VL - 313 ID - Galon2006 ER - TY - JOUR AU - Galon, J. AU - Pages, F. AU - Marincola, F. M. AU - Thurin, M. AU - Trinchieri, G. AU - Fox, B. A. PY - 2012 DA - 2012// TI - The immune score as a new possible approach for the classification of cancer JO - J Transl Med VL - 10 ID - Galon2012 ER - TY - JOUR AU - Galon, J. AU - Pages, F. AU - Marincola, F. M. AU - Angell, H. K. AU - Thurin, M. AU - Lugli, A. PY - 2012 DA - 2012// TI - Cancer classification using the Immunoscore: a worldwide task force JO - J Transl Med VL - 10 ID - Galon2012 ER - TY - JOUR AU - Galon, J. AU - Angell, H. K. AU - Bedognetti, D. AU - Marincola, F. M. PY - 2013 DA - 2013// TI - The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures JO - Immunity VL - 39 ID - Galon2013 ER - TY - JOUR AU - Angell, H. AU - Galon, J. PY - 2013 DA - 2013// TI - From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer JO - Curr Opin Immunol VL - 25 ID - Angell2013 ER - TY - JOUR AU - Galon, J. AU - Mlecnik, B. AU - Bindea, G. AU - Angell, H. K. AU - Berger, A. AU - Lagorce, C. PY - 2014 DA - 2014// TI - Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours JO - J Pathol VL - 232 ID - Galon2014 ER - TY - JOUR AU - Bindea, G. AU - Mlecnik, B. AU - Angell, H. K. AU - Galon, J. PY - 2014 DA - 2014// TI - The immune landscape of human tumors: implications for cancer immunotherapy JO - Oncoimmunology VL - 3 ID - Bindea2014 ER - TY - JOUR AU - Hamilton, P. W. AU - Bankhead, P. AU - Wang, Y. AU - Hutchinson, R. AU - Kieran, D. AU - McArt, D. G. PY - 2014 DA - 2014// TI - Digital pathology and image analysis in tissue biomarker research JO - Methods VL - 70 ID - Hamilton2014 ER - TY - JOUR AU - Schaeybroeck, S. AU - Allen, W. L. AU - Turkington, R. C. AU - Johnston, P. G. PY - 2011 DA - 2011// TI - Implementing prognostic and predictive biomarkers in CRC clinical trials JO - Nat Rev Clin Oncol VL - 8 ID - Schaeybroeck2011 ER - TY - JOUR AU - Schneider, M. R. AU - Wolf, E. PY - 2009 DA - 2009// TI - The epidermal growth factor receptor ligands at a glance JO - J Cell Physiol VL - 218 ID - Schneider2009 ER - TY - JOUR AU - Khambata-Ford, S. AU - Garrett, C. R. AU - Meropol, N. J. AU - Basik, M. AU - Harbison, C. T. AU - Wu, S. PY - 2007 DA - 2007// TI - Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab JO - J Clin Oncol VL - 25 ID - Khambata-Ford2007 ER - TY - JOUR AU - Jacobs, B. AU - Roock, W. AU - Piessevaux, H. AU - Oirbeek, R. AU - Biesmans, B. AU - Schutter, J. PY - 2009 DA - 2009// TI - Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab JO - J Clin Oncol VL - 27 ID - Jacobs2009 ER - TY - JOUR AU - Straussman, R. AU - Morikawa, T. AU - Shee, K. AU - Barzily-Rokni, M. AU - Qian, Z. R. AU - Du, J. PY - 2012 DA - 2012// TI - Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion JO - Nature VL - 487 ID - Straussman2012 ER - TY - JOUR AU - Wilson, T. R. AU - Fridlyand, J. AU - Yan, Y. AU - Penuel, E. AU - Burton, L. AU - Chan, E. PY - 2012 DA - 2012// TI - Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors JO - Nature VL - 487 ID - Wilson2012 ER - TY - JOUR AU - Kuramochi, H. AU - Nakajima, G. AU - Kaneko, Y. AU - Nakamura, A. AU - Inoue, Y. AU - Yamamoto, M. PY - 2012 DA - 2012// TI - Amphiregulin and epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases JO - BMC Cancer VL - 12 ID - Kuramochi2012 ER - TY - JOUR AU - Sunaga, N. AU - Kaira, K. AU - Imai, H. AU - Shimizu, K. AU - Nakano, T. AU - Shames, D. S. PY - 2013 DA - 2013// TI - Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer JO - Oncogene VL - 32 ID - Sunaga2013 ER - TY - JOUR AU - Oda, K. AU - Matsuoka, Y. AU - Funahashi, A. AU - Kitano, H. PY - 2005 DA - 2005// TI - A comprehensive pathway map of epidermal growth factor receptor signaling JO - Mol Syst Biol VL - 1 ID - Oda2005 ER - TY - JOUR AU - Mandell, J. W. PY - 2003 DA - 2003// TI - Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology JO - Am J Pathol VL - 163 ID - Mandell2003 ER - TY - JOUR AU - Chafin, D. AU - Theiss, A. AU - Roberts, E. AU - Borlee, G. AU - Otter, M. AU - Baird, G. S. PY - 2013 DA - 2013// TI - Rapid two-temperature formalin fixation JO - PLoS One VL - 8 ID - Chafin2013 ER - TY - JOUR AU - Theiss, A. P. AU - Chafin, D. AU - Bauer, D. R. AU - Grogan, T. M. AU - Baird, G. S. PY - 2014 DA - 2014// TI - Immunohistochemistry of colorectal cancer biomarker phosphorylation requires controlled tissue fixation JO - PLoS One VL - 9 ID - Theiss2014 ER - TY - JOUR AU - Phipps, A. I. AU - Limburg, P. J. AU - Baron, J. A. AU - Burnett-Hartman, A. N. AU - Weisenberger, D. J. AU - Laird, P. W. PY - 2015 DA - 2015// TI - Association between molecular subtypes of colorectal cancer and patient survival JO - Gastroenterology VL - 148 ID - Phipps2015 ER - TY - JOUR AU - Sadanandam, A. AU - Lyssiotis, C. A. AU - Homicsko, K. AU - Collisson, E. A. AU - Gibb, W. J. AU - Wullschleger, S. PY - 2013 DA - 2013// TI - A colorectal cancer classification system that associates cellular phenotype and responses to therapy JO - Nat Med. VL - 19 ID - Sadanandam2013 ER - TY - JOUR AU - Duncan, J. S. AU - Whittle, M. C. AU - Nakamura, K. AU - Abell, A. N. AU - Midland, A. A. AU - Zawistowski, J. S. PY - 2012 DA - 2012// TI - Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer JO - Cell VL - 149 ID - Duncan2012 ER - TY - JOUR AU - Ascierto, P. A. AU - Kirkwood, J. M. AU - Grob, J. -. J. AU - Simeone, E. AU - Grimaldi, A. M. AU - Maio, M. PY - 2012 DA - 2012// TI - The role of BRAF V600 mutation in melanoma JO - J Transl Med VL - 10 ID - Ascierto2012 ER - TY - JOUR AU - Flaherty, K. T. AU - Infante, J. R. AU - Daud, A. AU - Gonzalez, R. AU - Kefford, R. F. AU - Sosman, J. PY - 2012 DA - 2012// TI - Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations JO - N Engl J Med VL - 367 ID - Flaherty2012 ER - TY - JOUR AU - Larkin, J. AU - Ascierto, P. A. AU - Dréno, B. AU - Atkinson, V. AU - Liszkay, G. AU - Maio, M. PY - 2014 DA - 2014// TI - Combined vemurafenib and cobimetinib in BRAF-mutated melanoma JO - N Engl J Med VL - 371 ID - Larkin2014 ER - TY - JOUR AU - Polley, M. Y. AU - Leung, S. C. AU - McShane, L. M. AU - Gao, D. AU - Hugh, J. C. AU - Mastropasqua, M. G. PY - 2013 DA - 2013// TI - An international Ki67 reproducibility study JO - J Natl Cancer Inst VL - 105 ID - Polley2013 ER - TY - JOUR AU - Smits, A. J. AU - Kummer, J. A. AU - Bruin, P. C. AU - Bol, M. AU - Tweel, J. G. AU - Seldenrijk, K. A. PY - 2014 DA - 2014// TI - The estimation of tumor cell percentage for molecular testing by pathologists is not accurate JO - Mod Pathol VL - 27 ID - Smits2014 ER - TY - JOUR AU - Viray, H. AU - Li, K. AU - Long, T. A. AU - Vasalos, P. AU - Bridge, J. A. AU - Jennings, L. J. PY - 2013 DA - 2013// TI - A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells JO - Arch Pathol Lab Med VL - 137 ID - Viray2013 ER - TY - JOUR AU - Shaw, G. L. AU - Thomas, B. C. AU - Dawson, S. N. AU - Srivastava, G. AU - Vowler, S. L. AU - Gnanapragasam, V. J. PY - 2014 DA - 2014// TI - Identification of pathologically insignificant prostate cancer is not accurate in unscreened men JO - Br J Cancer VL - 110 ID - Shaw2014 ER - TY - JOUR AU - Foran, D. J. AU - Chen, W. AU - Yang, L. PY - 2011 DA - 2011// TI - Automated image interpretation computer-assisted diagnostics JO - Anal Cell Pathol [Amst] VL - 34 ID - Foran2011 ER - TY - JOUR AU - Riley, J. S. AU - Hutchinson, R. AU - McArt, D. G. AU - Crawford, N. AU - Holohan, C. AU - Paul, I. PY - 2013 DA - 2013// TI - Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer JO - Cell Death Dis VL - 5 ID - Riley2013 ER - TY - JOUR AU - Petrovski, S. AU - Goldstein, D. B. PY - 2014 DA - 2014// TI - Phenomics and the interpretation of personal genomes JO - Sci Transl Med VL - 6 ID - Petrovski2014 ER - TY - JOUR AU - Zemojtel, T. AU - Kohler, S. AU - Mackenroth, L. AU - Jager, M. AU - Hecht, J. AU - Krawitz, P. PY - 2014 DA - 2014// TI - Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome JO - Sci Transl Med VL - 6 ID - Zemojtel2014 ER - TY - JOUR AU - Lu, J. T. AU - Campeau, P. M. AU - Lee, B. H. PY - 2014 DA - 2014// TI - Genotype-phenotype correlation—promiscuity in the era of next-generation sequencing JO - N Engl J Med VL - 371 ID - Lu2014 ER - TY - JOUR AU - Zbuk, K. M. AU - Eng, C. PY - 2007 DA - 2007// TI - Cancer phenomics: RET and PTEN as illustrative models JO - Nat Rev Cancer VL - 7 ID - Zbuk2007 ER - TY - JOUR AU - Houle, D. AU - Govindaraju, D. R. AU - Omholt, S. PY - 2010 DA - 2010// TI - Phenomics: the next challenge JO - Nat Rev Genet VL - 11 ID - Houle2010 ER - TY - JOUR AU - Kelloff, G. J. AU - Sigman, C. C. PY - 2012 DA - 2012// TI - Cancer biomarkers: selecting the right drug for the right patient JO - Nat Rev Drug Discov VL - 11 ID - Kelloff2012 ER - TY - JOUR AU - Kent, D. M. AU - Rothwell, P. M. AU - Ioannidis, J. P. AU - Altman, D. G. AU - Hayward, R. A. PY - 2010 DA - 2010// TI - Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal JO - Trials VL - 11 ID - Kent2010 ER - TY - JOUR AU - Kleppe, M. AU - Levine, R. L. PY - 2014 DA - 2014// TI - Tumor heterogeneity confounds and illuminates: assessing the implications JO - Nat Med VL - 20 ID - Kleppe2014 ER - TY - JOUR AU - Cadioli, A. AU - Rossi, G. AU - Costantini, M. AU - Cavazza, A. AU - Migaldi, M. AU - Colby, T. V. PY - 2014 DA - 2014// TI - Lung cancer histologic and immunohistochemical heterogeneity in the era of molecular therapies: analysis of 172 consecutive surgically resected, entirely sampled pulmonary carcinomas JO - Am J Surg Pathol VL - 38 ID - Cadioli2014 ER - TY - JOUR AU - Baldus, S. E. AU - Schaefer, K. L. AU - Engers, R. AU - Hartleb, D. AU - Stoecklein, N. H. AU - Gabbert, H. E. PY - 2010 DA - 2010// TI - Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases JO - Clin Cancer Res VL - 16 ID - Baldus2010 ER - TY - JOUR AU - Xie, T. AU - Cho, Y. B. AU - Wang, K. AU - Huang, D. AU - Hong, H. K. AU - Choi, Y. L. PY - 2014 DA - 2014// TI - Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing JO - Genomics VL - 104 ID - Xie2014 ER - TY - JOUR AU - Modjtahedi, H. AU - Essapen, S. PY - 2009 DA - 2009// TI - Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities JO - Anticancer Drugs VL - 20 ID - Modjtahedi2009 ER - TY - JOUR AU - Modjtahedi, H. AU - Khelwatty, S. A. AU - Kirk, R. S. AU - Seddon, A. M. AU - Essapen, S. AU - Vecchio, C. A. PY - 2012 DA - 2012// TI - Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10 JO - Br J Cancer VL - 106 ID - Modjtahedi2012 ER - TY - JOUR AU - Fan, Q. W. AU - Cheng, C. K. AU - Gustafson, W. C. AU - Charron, E. AU - Zipper, P. AU - Wong, R. A. PY - 2013 DA - 2013// TI - EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma JO - Cancer Cell VL - 24 ID - Fan2013 ER - TY - JOUR AU - Bartlett, J. M. AU - Campbell, F. M. AU - Ibrahim, M. AU - O’Grady, A. AU - Kay, E. AU - Faulkes, C. PY - 2011 DA - 2011// TI - A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay JO - Am J Clin Pathol VL - 135 ID - Bartlett2011 ER - TY - JOUR AU - Wetering, M. AU - Sancho, E. AU - Verweij, C. AU - Lau, W. AU - Oving, I. AU - Hurlstone, A. PY - 2002 DA - 2002// TI - The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells JO - Cell VL - 111 ID - Wetering2002 ER - TY - JOUR AU - Chakrabarty, A. AU - Sanchez, V. AU - Kuba, M. G. AU - Rinehart, C. AU - Arteaga, C. L. PY - 2012 DA - 2012// TI - Feedback upregulation of HER3 [ErbB3] expression and activity attenuates antitumor effect of PI3K inhibitors JO - Proc Natl Acad Sci USA VL - 109 ID - Chakrabarty2012 ER - TY - JOUR AU - Laurent-Puig, P. AU - Manceau, G. AU - Zucman-Rossi, J. AU - Blons, H. PY - 2012 DA - 2012// TI - Dual blockade of epidermal growth factor receptor-induced pathways: a new avenue to treat metastatic colorectal cancer JO - J Clin Oncol VL - 30 ID - Laurent-Puig2012 ER -